Spanish flag Español
Medicina Interna Basada en la Evidencia

Portal para médicos

Guías: tratamiento de la diabetes tipo 2. Resumen

07.04.2023
Título original: Leczenie cukrzycy typu 2 – farmakoterapeutyczna rewolucja dokonana
Autores: prof. Leszek Czupryniak (MD, PhD), Ewa Płaczkiewicz‑Jankowska (MD, PhD), prof. Krzysztof Strojek (MD, PhD)

Resumen

La posición más reciente de ADA y EASD2 supone un cambio importante en el enfoque del tratamiento de la diabetes tipo 2. Este consiste, sobre todo, en tener una clara preferencia por iSGLT2 y GLP‑1 RA en todas las etapas de tratamiento, especialmente en enfermos con ECV, IC y/o ERC diagnosticada, así como en prestar mucha más atención a la reducción de la masa corporal. […] Esto no siempre será fácil, debido a los altos costos de tratamiento con fármacos de estos grupos, así como al hecho de que la disponibilidad global de GLP‑1 RA está limitada desde hace unos meses. […]

Volver al artículo principal: Guías: la revolución en la farmacoterapia de la diabetes tipo 2 es un hecho

Bibliografía:
  1. Nathan D.M., Buse J.B., Davidson M.B. y cols., Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 2006; 49: 1711‑1721
  2. Davies M.J., Aroda V.R., Collins B.S. y cols., Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 2022; 24: 1‑42
  3. Scirica B.M., Bhatt D.L., Braunwald E. y cols., SAVOR‑TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N. Engl. J. Med., 2013; 369: 1317‑1326
  4. White W.B., Cannon C.P., Heller S.R. y cols., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N. Engl. J. Med., 2013; 369: 1327‑1335
  5. Green J.B., Bethel M.A., Armstrong P.W. y cols., TECOS study group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes, N. Engl. J. Med., 2015; 373: 232‑342
  6. Rosenstock J., Perkovic V., Johansen O.E. i wsp.; CARMELINA Investigators: Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, JAMA, 2019; 321: 69‑79
  7. Zinman B., Wanner C., Lachin J.M. y cols.; EMPA‑REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N. Engl. J. Med., 2015; 373: 2117‑2128
  8. Wanner C., Inzucchi S.E., Lachin J.M. y cols., EMPA‑REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes, N. Engl. J. Med., 2016; 375: 323‑334
  9. Marso S.P., Daniels G.H., Brown‑Frandsen K. y cols.; LEADER Steering Committee: LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes, N. Engl. J. Med., 2016; 375: 311‑322
  10. Marso S.P., Bain S.C., Consoli A. y cols.; SUSTAIN‑6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 2016; 375: 1834‑1844
  11. Neal B., Perkovic V., Mahaffey K.W. y cols., Canagliflozin and cardiovascular and renal events in type 2 diabetes, N. Engl. J. Med., 2017; 377: 644‑657
  12. Mann J. F. E., Orsted D. D., Brown‑Frandsen K. y cols., Liraglutide and renal outcomes in type 2 diabetes, N. Engl. J. Med., 2017; 377: 839‑848
  13. Wiviott S. D., Raz I., Bonaca M. P. y cols., Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N. Engl. J. Med., 2019; 380: 347‑357
  14. Perkovic V., Jardine M.J., Neal B. y cols., Canagliflozin and renal out comes in type 2 diabetes and nephropathy, N. Engl. J. Med., 2019; 380: 2295‑2306
  15. Gerstein H.C., Colhoun H.M., Dagenais G.R. y cols., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial, Lancet, 2019; 394: 121‑130
  16. Gerstein H.C., Colhoun H.M., Dagenais G.R. y cols., Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‑controlled trial, Lancet, 2019; 394: 131‑138
  17. Husain M., Birkenfeld A.L., Donsmark M. y cols., Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 2019; 381: 841‑851
  18. Tsapas A., Avgerinos I., Karagiannis T. y cols., Comparative effectiveness of glucose‑lowering drugs for type 2 diabetes: a systematic review and network meta‑analysis, Ann. Intern. Med., 2020; 173: 278‑286
  19. Tsapas A., Karagiannis T., Kakotrichi P. y cols., Comparative efficacy of glucose‑lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta‑analysis, Diabetes Obes. Metab., 2021; 23: 2116‑2124
  20. McMurray J.J.V., Solomon S.D., Inzucchi S.E. y cols., Dapagliflozin in patients with heart failure and reduced ejection fraction, N. Engl. J. Med., 2019; 381: 1995‑2008
  21. Packer M., Anker S.D., Butler J. y cols., Cardiovascular and renal outcomes with empagliflozin in heart failure, N. Engl. J. Med., 2020; 383: 1413‑1424
  22. Heerspink H.J.L., Stefánsson B.V., Correa‑Rotter R. y cols., Dapagliflozin in patients with chronic kidney disease, N. Engl. J. Med., 2020; 383: 1436‑1446
  23. Anker S.D., Butler J., Filippatos G. y cols., Empagliflozin in heart failure with a preserved ejection fraction, N. Engl. J. Med., 2021; 385: 1451‑1461
  24. Solomon S.D., McMurray J.J.V., Claggett B. y cols., Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction, N. Engl. J. Med., 2022; 387: 1089‑1098
  25. EMPA‑KIDNEY Collaborative Group, Design, recruitment, and baseline characteristics of the EMPA‑KIDNEY trial, Nephrol. Dial. Transplant., 2022; 37: 1317‑1329
  26. Davies M.J., D’Alessio D.A., Fradkin J. y cols., Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 2018; 61: 2461‑2498
  27. Buse J.B., Wexler D.J., Tsapas A. y cols., 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 2020; 63: 221‑228
  28. Czupryniak L., Strojek K., Zasady współczesnej farmakoterapii cukrzycy typu 2 według stanowiska ADA i EASD 2018, Med. Prakt., 2019; 1: 13‑26
  29. Polskie Towarzystwo Diabetologiczne, Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2022, Curr. Top Diabetes, 2022; 2: 1‑133
  30. Matthew C., Riddle M.C., Cefalu W.T. y cols., Consensus report: definition and Interpretation of remission in type 2 diabetes, Diabetes Care, 2021; 44: 2438‑2444
  31. Palmer S.C., Tendal B., Mustafa R.A. y cols., Sodium‑glucose cotransporter protein‑2 (SGLT‑2) inhibitors and glucagon‑like peptide‑1 (GLP‑1) receptor agonists for type 2 diabetes: systematic review and network meta‑analysis of randomized controlled trials, BMJ, 2021; 372: m4573
  32. Matthews D.R., Paldánius P.M., Proot P. y cols., Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5‑year, multicentre, randomised, double‑blind trial, Lancet, 2019, 394: 1519‑1529
  33. Karagiannis T., Tsapas A., Athanasiadou E. y cols., GLP‑1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta‑analysis, Diabetes Res. Clin. Pract., 2021; 174: 108737
  34. Chan J.C.N., Paldánius P.M., Mathieu C. y cols., Early combination therapy delayed treatment escalation in newly diagnosed young‑onset type 2 diabetes: a subanalysis of the VERIFY study, Diabetes Obes. Metab., 2021; 23: 245‑251